Commentary

Video

Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, Kidney Cancer Program, senior physician, Dana-Farber Cancer Institute, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, discusses the phase 3 TiNivo-2 study (NCT04987203) in pretreated advanced renal cell carcinoma (RCC).

TiNivo-2 is a randomized trial comparing tivozanib (Fotivda) plus nivolumab (Opdivo) vs tivozanib monotherapy in patients with RCC following disease progression on 1 or 2 prior lines of therapy, including an immune checkpoint inhibitor. The study is fully accrued, and findings are expected later this year; the results could potentially be practice altering if a benefit is observed with immune checkpoint inhibitor rechallenge, Choueiri says.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Alberto Montero, MD, MBA, CPHQ